Literature DB >> 29928380

MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1.

Sida Liu1, Yang Yang2, Lu Chen2, Danwei Liu3, Han Dong4.   

Abstract

Lung cancer remains the leading cause of cancer-associated mortality in China and worldwide. Increasing numbers of studies have demonstrated that microRNAs (miRNAs/miRs) have vital functions in numerous developmental processes and tumorigenesis. The aim of the present study was to investigate miR-154 expression in non-small cell lung cancer (NSCLC), and to explore the roles of miR-154 in the carcinogenesis and progression of this cancer. Reverse transcription-polymerase chain reaction (RT-qPCR) was performed to detect miR-154 expression in NSCLC tissues and cell lines. In addition, cell proliferation assay, migration and invasion assays were adopted to investigate the functional roles of miR-154 in NSCLC. Bioinformatics analysis, luciferase reporter assay, RT-qPCR and western blot analysis were used to explore the potential targets of miR-154 in NSCLC. According to the results, miR-154 was significantly downregulated in NSCLC tissues and cell lines. Restoration of miR-154 expression inhibited proliferation, migration and invasion of NSCLC cells. In addition, B-cell-specific Moloney murine leukemia virus insertion site 1 (BMI-1) was identified as a direct target gene of miR-154 in NSCLC. In conclusion, miR-154 may function as a tumor suppressor in NSCLC, partly by regulating BMI-1, and the modulation of miR-154 expression represents a potential strategy for the treatment of NSCLC patients.

Entities:  

Keywords:  B-cell-specific Moloney murine leukemia virus insertion site 1; metastasis; microRNA-154; non-small cell lung cancer; proliferation

Year:  2018        PMID: 29928380      PMCID: PMC6004722          DOI: 10.3892/ol.2018.8595

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo.

Authors:  Xingyu Lin; Zhiguang Yang; Peng Zhang; Guoguang Shao
Journal:  Oncol Rep       Date:  2015-04-02       Impact factor: 3.906

Review 2.  Non-small-cell lung cancer.

Authors:  Peter Goldstraw; David Ball; James R Jett; Thierry Le Chevalier; Eric Lim; Andrew G Nicholson; Frances A Shepherd
Journal:  Lancet       Date:  2011-05-10       Impact factor: 79.321

Review 3.  MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.

Authors:  Achim Aigner
Journal:  J Mol Med (Berl)       Date:  2011-01-14       Impact factor: 4.599

Review 4.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

Authors:  William C S Cho
Journal:  Int J Biochem Cell Biol       Date:  2009-12-22       Impact factor: 5.085

5.  Time trends in cancer mortality in China: 1987-1999.

Authors:  Ling Yang; Donald M Parkin; Liandi Li; Yude Chen
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

6.  miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells.

Authors:  Chen Zhu; Jie Li; Gong Cheng; Hai Zhou; Liangjun Tao; Hongzhou Cai; Pu Li; Qiang Cao; Xiaobing Ju; Xiaoxin Meng; Meilin Wang; Zhengdong Zhang; Chao Qin; Lixin Hua; Changjun Yin; Pengfei Shao
Journal:  Mol Cell Biochem       Date:  2013-04-17       Impact factor: 3.396

7.  miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2.

Authors:  Chaoguang Xin; Hao Zhang; Zanchao Liu
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

8.  MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways.

Authors:  Dongmei Li; Yucheng Wei; Dong Wang; Huijiang Gao; Kui Liu
Journal:  Biochem Biophys Res Commun       Date:  2016-01-28       Impact factor: 3.575

9.  miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer.

Authors:  Yan Hou; Junwen Zhen; Xiaodong Xu; Kun Zhen; Bin Zhu; Rui Pan; Chidong Zhao
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  4 in total

1.  P53/miR-154 Pathway Regulates the Epithelial-Mesenchymal Transition in Glioblastoma Multiforme Cells by Targeting TCF12.

Authors:  Gang Zhu; Shirong Yang; Ronglin Wang; Jie Lei; Peigang Ji; Jiancai Wang; Kai Tao; Chen Yang; Shunnan Ge; Liang Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-02-26       Impact factor: 2.570

Review 2.  The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies.

Authors:  Jie Xu; Lin Li; Pengfei Shi; Hongjuan Cui; Liqun Yang
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

3.  Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.

Authors:  Zahra Bolandghamat Pour; Mitra Nourbakhsh; Kazem Mousavizadeh; Zahra Madjd; Seyedeh Sara Ghorbanhosseini; Zohreh Abdolvahabi; Zahra Hesari; Samira Ezzati Mobasser
Journal:  BMC Cancer       Date:  2019-11-01       Impact factor: 4.430

4.  miR-154 Influences HNSCC Development and Progression through Regulation of the Epithelial-to-Mesenchymal Transition Process and Could Be Used as a Potential Biomarker.

Authors:  Weronika Tomaszewska; Joanna Kozłowska-Masłoń; Dawid Baranowski; Anna Perkowska; Sandra Szałkowska; Urszula Kazimierczak; Patricia Severino; Katarzyna Lamperska; Tomasz Kolenda
Journal:  Biomedicines       Date:  2021-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.